U.S. FDA And European Medicines Agency Accepted Pfizer's Hair Loss Candidate Submission For Review

The U.S. Food and Drug Administration (FDA) has accepted for review Pfizer’s (NYSE: PFE) New Drug Application (NDA) for ritlecitinib for adults and adolescents 12 years of age and older with alopecia areata. The regulatory agency is expected to make a decision in the second-quarter of 2023.